Pharmaceutical Executive
KOLs have traditionally exerted their influence through research and publication on drug safety and efficacy, but now share the stage with other important measures.
Paul Chew, MD
Advertisement
Articles by Paul Chew, MD
Pharmaceutical Executive
A discussion of the cost and time put into clinical trials.
Advertisement
Latest Updated Articles
- KOLs: An Endangered Buzzword
March 20th 2019
Advertisement
Advertisement
Trending on PharmExec
1
Pharmaceutical Executive Daily: AbbVie and Haisco Enter $745 Million Licensing Agreement
2
How Are Regulatory Factors Impacting Biosimilars
3
Travere Therapeutics’ Filspari Receives Full FDA Approval
4
How Serious is the Biosimilar Void?
5